Major depressive disorder

• 1. Introduction

  ›

  Major depressive disorder sits at the center of a quiet global crisis. It has been diagnosed in approximately 163 million people worldwide, and yet for much of recorded history, no one agreed on what to call it, what caused it, or how to treat it. The disorder goes by another name many people recognize immediately: clinical depression. But the clinical label itself is surprisingly young, introduced by a group of American clinicians only in the mid-1970s and formally adopted by the American Psychiatric Association in 1980.

  What does it actually mean to have this disorder? At minimum, two weeks of pervasive low mood, a loss of self-esteem, and a collapse of interest or pleasure in things that once brought enjoyment. Those are the diagnostic floor. But the full picture is far wider and stranger than that floor suggests. Some people become physically unable to move. Others develop hallucinations. Many find their memory and concentration eroding alongside their mood. And across the world, the disorder manifests differently depending on where someone lives, because culture shapes which symptoms a person notices and which ones they report.

  Why do some people develop it and others do not? What goes wrong in the brain, and does the popular explanation involving serotonin actually hold up? How did medicine move from the ancient Greek idea of melancholia to a precise diagnostic checklist? And what does a Norwegian prime minister's three-week absence from office in 1998 tell us about stigma? These are the threads this documentary will follow.

• 2. A Disorder With Ancient Roots

  ›

  Hippocrates, the ancient Greek physician, described a condition he called melancholia, naming it after the Greek words for black bile. His account was broader than today's diagnosis: all fears and despondencies that lasted a long time qualified, and the cluster of symptoms included sadness, dejection, anger, delusions, and obsessions. What he was describing was recognizable enough to survive in medical thinking for more than two thousand years.

  The word depression itself took a different path. It comes from the Latin verb deprimere, meaning to press down. By the 14th century, to depress something meant to subjugate it or to bring down its spirits. English author Richard Baker used the phrase "a great depression of spirit" in his Chronicle in 1665. Samuel Johnson used it in a similar sense in 1753. The French psychiatrist Louis Delasiauve gave it its first clearly psychiatric use in 1856, and by the 1860s medical dictionaries were adopting it to describe a lowering of emotional function.

  German psychiatrist Emil Kraepelin may have been the first to use depression as an overarching clinical term, grouping different kinds of melancholia under what he called depressive states. Sigmund Freud took the conversation further in his 1917 paper Mourning and Melancholia, arguing that melancholia resembled grief but cut deeper. Where mourning is a response to the external loss of something, melancholia, in Freud's view, drew the wound inward: the person identified so closely with what was lost that the loss registered as a defect in the self, producing guilt, inferiority, and feelings of unworthiness.

  Adolf Meyer pushed back against the melancholia frame entirely, arguing that depression should replace it. The first edition of the Diagnostic and Statistical Manual, published in 1952, used the term depressive reaction. The second edition, in 1968, shifted to depressive neurosis. Then a group of US clinicians in the mid-1970s proposed precise diagnostic criteria built on patterns of symptoms, and the term major depressive disorder entered the DSM-III in 1980, splitting off from the older depressive neurosis category. The ancient idea of melancholia did not disappear, however. It survives today as one of the named subtypes recognized by the DSM-5.

• 3. What the Disorder Actually Looks Like

  ›

  Approximately 50% of individuals with major depressive disorder report a complete loss of emotional reactivity, a state researchers call anhedonia or emotional blunting. It is not sadness so much as a neurological protection response, a flattening of the entire emotional register. For those people, the disorder does not feel like intense pain. It feels like nothing at all.

  Beyond that core experience, the symptom profile is strikingly broad. Poor concentration and memory, withdrawal from social situations, reduced sex drive, and irritability are common. Sleep is frequently disrupted: in the typical pattern, a person wakes very early and cannot return to sleep. Hypersomnia, or oversleeping, can also occur, as can a pattern in which mood worsens at a specific time of day, a phenomenon known as diurnal mood variation. Appetite often drops, leading to weight loss, though increased appetite and weight gain are also possible.

  In severe cases, psychotic symptoms emerge. Delusions are more common than hallucinations, and both tend to be unpleasant in character. People who have experienced psychotic symptoms in one episode are more likely to have them again in future episodes.

  Children with the disorder frequently show a different face than adults. Irritability often replaces the classic low mood, and most lose interest in school, showing a steep decline in academic performance. Diagnoses in children are frequently missed because the symptoms are mistaken for normal moodiness. Elderly people with depression may not present with classical depressive symptoms either, and treatment is further complicated because older patients are often taking multiple medications for other conditions simultaneously.

  In developing countries, the World Health Organization has documented that physical complaints are the most common presenting problem for people with depression. Headaches, fatigue, and digestive issues often come before any mention of emotional distress. That pattern matters clinically, because it means the disorder can be overlooked entirely when a clinician is looking for mood symptoms and a patient is describing a stomachache.

  The disorder also reshapes relationships. Family and friends may notice agitation or lethargy. Major depression significantly affects work or school life, eating habits, and general health. A 2025 study of more than 172,500 adults in the UK aged 39 and older found that those with a history of depression experienced the onset of chronic illnesses approximately 30% earlier than those without depression.

• 4. Why It Happens: Biology and Environment

  ›

  Family and twin studies suggest that genetic factors account for nearly 40% of the variation in risk for major depressive disorder. A genome-wide association study in 2018 identified 44 genetic variants linked to risk for major depression, and a 2019 study raised that count to 102 variants. Despite those findings, major depression appears less heritable than bipolar disorder or schizophrenia, and researchers have been cautious about candidate-gene studies, which have a documented tendency to generate false positive results.

  The most widely known biological explanation is the monoamine theory, which proposes that insufficient activity of neurotransmitters such as serotonin, dopamine, and norepinephrine underlies depression. The theory gained traction partly because drugs that increase monoamine activity often relieve depressive symptoms. But the theory has significant gaps. Depleting serotonin does not cause depression in healthy people. Antidepressants raise monoamine levels within hours, yet clinical improvement takes weeks. A 2022 review found no consistent evidence supporting the hypothesis that serotonin levels are the primary driver of depression. Researchers have proposed partial explanations for that lag, involving desensitization of feedback mechanisms in the brain, but the monoamine theory remains incomplete.

  The HPA axis, the body's central stress-response system, also shows abnormalities in people with depression. Stress-related changes in that system are thought to contribute to the reductions in hippocampal volume that have been observed in depressed individuals. Separately, neuroimaging has generated competing models: the limbic-cortical model proposes hyperactivity in emotional-processing regions and underactivity in frontal regulatory areas, while other models focus on circuits governing salience and reward.

  More recently, research in psychoneuroimmunology has pointed to inflammation. People with depression often show elevated levels of pro-inflammatory cytokines. The kynurenine pathway, which becomes overactivated in certain inflammatory states, can produce quinolinic acid; post-mortem studies have found higher levels of quinolinic acid in the brains of people who had major depressive disorder, and the concentration appears to correlate with symptom severity. The gut-brain axis has also drawn research attention, with studies showing that people with major depressive disorder carry different gut bacteria than healthy controls, particularly in the Bacteroidetes and Firmicutes populations.

  On the environmental side, adverse childhood experiences, including abuse, neglect, and family dysfunction, markedly increase risk, especially when more than one type of adversity is present. Childhood trauma also correlates with poorer treatment response and longer episodes. People who live alone carry a 42% greater risk of depression, according to one review. Long-term exposure to particulate matter air pollution has been linked to depression, and there may be an association between short-term PM10 exposure and suicide.

• 5. Diagnosing the Disorder

  ›

  There is no laboratory test for major depressive disorder. Blood work is done, but its purpose is to rule out physical conditions that can mimic the symptoms: thyroid dysfunction, metabolic disturbances, systemic infections. The diagnosis itself rests on the person's reported experiences, observations from family or friends, and a mental state examination.

  The two primary diagnostic systems are the American Psychiatric Association's DSM and the World Health Organization's International Statistical Classification of Diseases, the ICD. The United States and many non-European countries use the DSM; European countries generally use the ICD. The authors of both systems have worked toward convergence. The current editions are the DSM-5-TR and the ICD-11.

  Under DSM-5, at least five of nine specific symptoms must occur most of the time for more than two weeks, to the degree that they impair functioning. At least one of those five must be either depressed mood or loss of interest or pleasure. The ICD-11 uses a similar threshold but adds severity specifiers for mild, moderate, and severe episodes, and notes whether psychotic symptoms are present.

  The DSM-5 also recognizes six subtypes, called specifiers. Melancholic depression is defined by a profound loss of pleasure and early-morning waking. Atypical depression involves mood reactivity and a sensitivity to perceived interpersonal rejection that causes long-term social impairment. Catatonic depression, which is rare, involves near-total muteness and either immobility or purposeless, bizarre movements. Depression with peripartum onset covers episodes during pregnancy or within one month of delivery, with an incidence rate of 3% to 6% among new mothers. Seasonal affective disorder requires at least two episodes in colder months with none at other times, over a period of at least two years.

  Non-psychiatrist physicians miss about two-thirds of depression cases, though there is some evidence that this rate has been improving. In rural areas, specialist mental health services are rare, and most diagnosis and management falls to primary-care clinicians. That gap is even more pronounced in developing countries, where the disorder is sometimes viewed as a phenomenon of wealthy nations despite evidence showing the opposite.

• 6. Treatment: What Works and What Remains Contested

  ›

  SSRIs are the most commonly prescribed antidepressants because of their relatively mild side-effect profile. Response rates to a first antidepressant range from 50% to 75%, and it can take at least six to eight weeks from the start of medication before improvement appears. People who do not respond to one SSRI can switch to another, with improvement seen in almost 50% of those cases. Treatment is usually continued for six to nine months after remission, with continuation of up to two years recommended in some cases.

  Cognitive behavioral therapy, or CBT, is the most extensively studied form of psychotherapy for depression. It teaches clients to challenge self-defeating patterns of thought and change counter-productive behaviors. CBT can perform as well as antidepressants in people with major depression and is particularly strong at preventing relapse. For people under 18, psychotherapy is the preferred treatment over medication; the UK National Institute for Health and Care Excellence specifies that antidepressants should not be used as initial treatment for mild depression in this age group because the risk-benefit ratio is poor.

  Lithium has a distinctive record in the treatment of severe and recurrent depression. Lithium augmentation has proven efficacy across multiple randomized controlled trials. The risk of suicide is reduced by 87% in people with depression or bipolar disorder who take lithium, and it also lowers the risk of mortality from all causes.

  Electroconvulsive therapy, or ECT, is effective for about 50% of people with treatment-resistant major depressive disorder. A typical course involves six to twelve treatments, administered two or three times a week under anesthesia with a muscle relaxant. The most common immediate adverse effects are confusion and memory loss. ECT is considered one of the least harmful treatment options available for severely depressed pregnant women.

  In March 2019, the FDA approved a nasal spray form of esketamine for treatment-resistant depression when combined with an oral antidepressant. In January 2025, it was approved as a monotherapy for treatment-resistant depression in adults. In Australia, psilocybin was approved for treatment-resistant depression in 2023.

  Transcranial magnetic stimulation received FDA approval for treatment-resistant major depressive disorder in 2008, with endorsements from the American Psychiatric Association and peer bodies in Canada and Australia-New Zealand. St. John's Wort has approval in the European Union as a herbal product for mild to moderate depression and has been shown to be more effective than placebo and as effective as standard antidepressants for that severity range.

  Preventive interventions have shown measurable results. The Netherlands operates a program called the Coping with Depression course for people with sub-threshold depression, which claims a risk reduction of 38% in major depression. The United States Preventive Services Task Force has since 2016 recommended screening for depression in those over the age of 12, though a 2005 Cochrane review found that routine use of screening questionnaires has little effect on detection or treatment in the general population.

• 7. Stigma, Culture, and Public Life

  ›

  In August 1998, while serving his first term as Prime Minister of Norway, Kjell Magne Bondevik announced publicly that he was suffering from a depressive episode. He was the highest-ranking world leader to admit to having a mental illness while in office. Anne Enger became acting Prime Minister for three weeks, from the 30th of August to the 23rd of September, while he recovered. Bondevik returned to office, received thousands of supportive letters, and said the experience had been positive overall because it helped make mental illness more publicly acceptable.

  Historical figures who may have experienced depression include English author Mary Shelley, American-British writer Henry James, and American president Abraham Lincoln. Among more recent figures, Canadian songwriter Leonard Cohen and American playwright and novelist Tennessee Williams have been discussed in this context. English philosopher John Stuart Mill described a period of what he called a dull state of nerves, quoting the poet Samuel Taylor Coleridge's Dejection as the perfect description: "A grief without a pang, void, dark and drear."

  English writer Samuel Johnson used the phrase "the black dog" in the 1780s to describe his own depression. British Prime Minister Winston Churchill, who also had the disorder, subsequently popularized the phrase.

  Cultural context shapes which symptoms people report and which they suppress. In collectivistic cultures, people with depression tend to present more somatic symptoms and fewer affective ones compared to people in individualistic cultures. The explanation offered in research is that individualistic cultures are more accepting of the expression of emotional distress, while collectivistic cultures treat such expression as inconsistent with the social cooperation they prioritize.

  The gender gap in diagnosis is documented but not fully explained. Major depression is about twice as common in women as in men. The disparity is associated with pubertal development rather than chronological age, and reaches adult ratios between ages 15 and 18. It appears linked more to psychosocial factors than to hormonal ones. At the same time, men are significantly less likely to seek help: approximately 33.2% of men with depressive symptoms report seeking professional help, compared to 43.0% of women, with social pressures around masking likely playing a role.

  In the UK, a joint Five-Year Defeat Depression campaign by the Royal College of Psychiatrists and the Royal College of General Practitioners ran from 1992 to 1996. A MORI study conducted afterward showed a small positive change in public attitudes toward depression and its treatment. Social stigma for major depression remains widespread, and contact with mental health services reduces it only slightly.

• 8. Scale, Prognosis, and the Long View

  ›

  Studies have found that 80% of those who experience a first major depressive episode will have at least one more during their lifetime, with a lifetime average of four episodes. About half of people who have an episode recover and remain well; the other half will have at least one more, and around 15% experience chronic recurrence. For those with severe or psychotic depression, recurrence rates approach 90%.

  Major depressive episodes often resolve over time even without treatment. Among untreated adults with mild to moderate depression, a 2013 review found that 23% will remit within three months, 32% within six months, and 53% within twelve months. The median episode duration has been estimated at 23 weeks, with the highest rate of recovery occurring in the first three months.

  The economic and social footprint of the disorder is substantial. The combination of clinical care and supported return to work reduces sick leave by an annual average of 25 days per year. As of 2006, major depression was the leading cause of disease burden in North America and other high-income countries. The World Health Organization has projected that it will be the second-leading cause of disease burden worldwide in 2030, after HIV/AIDS.

  The disorder causes the second-most years lived with disability of any condition globally, after lower back pain. In the United States, 8.4% of adults, or 21 million individuals, have at least one episode within a given year. The probability is highest for those aged 18 to 25, at 17%.

  About 2% to 8% of adults with major depression die by suicide. The lifetime risk associated with a diagnosis is estimated at 7% for men and 1% for women in the US, even though suicide attempts are more frequent among women. About 50% of people who die of suicide have a mood disorder such as major depression. People with the disorder also face a 1.5 to 2-fold increased risk of cardiovascular disease, independent of other known risk factors.

  Only about 35% of those suffering from major depressive disorder worldwide seek help from a professional. That gap between the scale of the condition and the number of people receiving care remains one of the central unresolved problems in global mental health, and it is one that Kjell Magne Bondevik, answering reporters' questions in Oslo in 1998, had already decided to address in the most direct way available to him.